Fig. 2 From: Outcomes from a mechanistic biomarker multi-arm and randomised study of liposomal MTP-PE (Mifamurtide) in metastatic and/or recurrent osteosarcoma (EuroSarc-Memos trial)a. Summary of treatments administered and major patient events for each patient in all arms. b. Summary of the timing and of worst adverse events for each patient in all armsBack to article page